Roivant's Cash, Patent Wins, and Drug Approvals Drive Record High
Cash and Moderna Settlement Roivant ended fiscal 2026 with $4.3 billion in cash and a $2.25 billion settlement from Moderna over patent litigation. This huge cash pile gives Roivant the financial firepower to fund its drug pipeline and return value to shareholders, supporting the stock price.
This is a major new financial event that strengthens the balance sheet and reduces risk.
New Patent Lawsuits Against Pfizer and BioNTech Roivant's subsidiary Genevant filed new patent lawsuits against Pfizer and BioNTech over COVID vaccine technology, seeking injunctions and damages. If successful, these could bring in more settlement money like the Moderna deal, adding potential upside to ROIV shares.
This is a new legal action that could lead to future cash inflows, directly affecting ROIV's value.
FDA Approval and Launch of Lisraya The FDA approved Priovant's Lisraya for dermatomyositis, and it launched at $35,000 per month. As the first targeted therapy for a rare disease, it could generate significant revenue, though adoption may be gradual due to the high price and small patient pool.
This is a new product approval and launch, a key commercial milestone that drives future revenue.
Positive Lung Disease Trial Results Roivant's drug mosliciguat met its primary endpoint in a phase 2 trial for pulmonary hypertension with interstitial lung disease, sending the stock to an all-time high. This success opens a large market opportunity and validates Roivant's pipeline, boosting investor confidence.
This is a new clinical win that directly caused a major stock rally and highlights future growth potential.